Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem Industries has submitted a disclosure under SEBI Listing Regulations confirming that as of 30th September 2025, the company has no unutilized funds from any past public issue, rights issue, preferential issue, or qualified institutional placement (QIP). Since there are no proceeds pending utilization, the company is not required to file the standard deviation/variation statement (Annexure-A). This is a routine compliance filing with no new fund-raising activity or capital expenditure being reported. The letter is signed by Wholetime Director Kelash Bunkar and addressed to BSE.
This is a routine compliance disclosure with no material impact on shareholders or the stock price. It simply confirms there are no leftover funds from past issues requiring reporting, indicating neutral compliance posture.